Nogapendekin Alfa Inbakicept-pmln (Anktiva) — CPB 1059 | AETNA Coverage Update

Aetna modified CPB 1059 for nogapendekin alfa inbakicept-pmln (Anktiva), effective December 11, 2025. Here's what billing teams need to do before claims start flying.

Aetna, a CVS Health company, updated its Anktiva coverage policy under CPB 1059 Aetna system to define medical necessity criteria for HCPCS code J9028 — the billing code for nogapendekin alfa inbakicept-pmln — for BCG-unresponsive non-muscle invasive bladder cancer. This is a drug that pairs with BCG therapy (J9030, CPT 90586) in a tightly sequenced regimen, and Aetna's policy now spells out exactly when it will pay. If your team bills bladder cancer drug therapy for commercial plan members, this affects your prior authorization workflow starting December 11, 2025.

---

Quick Reference

Field	Detail
Payer	Aetna, a CVS Health company
Policy	Nogapendekin Alfa Inbakicept-pmln (Anktiva) — CPB 1059
Policy Code	CPB 1059
Change Type	Modified
Effective Date	December 11, 2025
Impact Level	High
Specialties Affected	Urology, Oncology, Hematology/Oncology, Hospital Outpatient
Key Action	Confirm prior authorization is in place before billing J9028 — every single dose requires precertification

---

Aetna Nogapendekin Alfa Inbakicept-pmln Coverage Criteria and Medical Necessity Requirements 2025

Aetna's Anktiva coverage policy requires you to check four boxes before they'll consider J9028 medically necessary. Miss one, and you have a denial — not just a delay.

The four criteria for initial approval:

First, the member must have non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Papillary tumors may or may not be present. The ICD-10 diagnosis code needs to reflect this — D09.0 (carcinoma in situ of bladder) or the appropriate C67.x code for bladder malignancy.

Second, the disease must be BCG-unresponsive. That word "unresponsive" is doing a lot of work here. Your medical records documentation needs to show prior BCG therapy and failure. If that clinical history isn't in the chart, your prior authorization request will fail before Aetna reads the rest of it.

Third, Anktiva must be used in combination with BCG — not as monotherapy. That means J9028 and J9030 (or CPT 90586) should appear together on your claims. A claim for J9028 alone, without BCG, is going to raise flags.

Fourth, the member must receive maintenance doses at months 4, 7, 10, 13, and 19 after induction therapy. This is a long treatment course — 37 months total if continuation is approved. That maintenance schedule isn't optional. It's a condition of medical necessity under this coverage policy.

Prior authorization is not optional here. Aetna requires precertification for every member on every applicable plan design. Call (866) 752-7021 or fax (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Build this into your workflow before the first dose gets administered, not after.

The Anktiva nogapendekin alfa inbakicept-pmln billing process is more complex than a typical drug claim. You're managing a combination regimen with a structured maintenance schedule across more than three years. Your authorization team needs a tickler system for those month 4, 7, 10, 13, and 19 maintenance visits — because reauthorization is required at each stage.

---

Aetna Anktiva Exclusions and Non-Covered Indications

This one is simple, and Aetna made it explicit: every indication outside of BCG-unresponsive NMIBC with CIS is experimental, investigational, or unproven.

There are no carve-outs. There is no off-label pathway defined in CPB 1059 for muscle-invasive bladder cancer, upper urinary tract cancers, or any other tumor type. If a provider requests Anktiva for anything other than the defined indication, Aetna will deny it — and they've put that in writing.

The real exposure here is off-label use in academic or research settings. If your facility treats complex oncology cases where providers sometimes use agents outside their labeled indication, make sure your team knows this boundary. A denial on J9028 for an unsupported indication is hard to appeal without a policy pathway, and CPB 1059 doesn't leave one open.

---

Coverage Indications at a Glance

Indication	Status	Relevant Codes	Notes Copy
BCG-unresponsive NMIBC with CIS (with or without papillary tumors), used in combination with BCG, with maintenance dosing schedule	Covered	J9028, J9030, CPT 90586, CPT 51720, D09.0, C67.x	Prior authorization required; all four criteria must be met
BCG-unresponsive NMIBC with CIS — continuation of therapy (up to 24 maintenance doses over 37 months)	Covered (Reauthorization Required)	J9028, J9030, CPT 90586	No evidence of unacceptable toxicity or disease progression required at reauth
All other indications (any off-label use)	Not Covered — Experimental/Investigational	J9028	Aetna considers all other uses experimental or unproven

---

Aetna Nogapendekin Alfa Inbakicept-pmln Billing Guidelines and Action Items 2025

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Nogapendekin Alfa Inbakicept-pmln Under CPB 1059

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
J9028	HCPCS	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

Related CPT and HCPCS Codes (Supporting the Regimen)

These codes are tied to CPB 1059 but are not independently covered under this bulletin's criteria. They support the combination regimen and should appear on claims alongside J9028 when clinically appropriate.

Code	Type	Description Copy
51720	CPT	Bladder instillation of anticarcinogenic agent (including retention time)
90586	CPT	Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use
J9030	HCPCS	BCG live intravesical instillation, 1 mg

Key ICD-10-CM Diagnosis Codes

A note on ICD-10 selection: D09.0 is your primary code for CIS, which is the core covered indication. The C67.x codes cover concurrent papillary tumors or the broader bladder malignancy. NMIBC with CIS can present with or without papillary lesions — make sure the codes on the claim reflect the complete clinical picture. If your provider documents both CIS and papillary tumors, bill both.

---

The Real Issue with This Policy

This is a 37-month regimen with a mandatory maintenance schedule. That's not a short-term drug approval — it's a long-term reimbursement commitment that requires your billing team to stay active across three-plus years of patient treatment.

Most claim denial problems on specialty drug regimens don't come from the initial authorization. They come from lapsed reauthorizations at month seven or month ten, when the patient's still in treatment but nobody submitted the reauth paperwork. With Anktiva, each maintenance window is a potential break point.

If you're managing Anktiva billing for even a handful of patients, assign a dedicated person to track that maintenance schedule. The upside — and there is an upside here — is that Aetna's criteria are actually clear. Four conditions for initial approval, one condition for continuation (no toxicity or progression). That's a policy you can build a workflow around. Compared to some specialty drug policies that leave criteria vague, this one gives your team something to work with.

If you're uncertain how this applies to your specific plan mix or patient population, talk to your compliance officer before December 11, 2025.

---